Uniqure NV
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. Th… Read more
Uniqure NV (QURE) - Net Assets
Latest net assets as of September 2025: $228.75 Million USD
Based on the latest financial reports, Uniqure NV (QURE) has net assets worth $228.75 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($888.38 Million) and total liabilities ($659.64 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $228.75 Million |
| % of Total Assets | 25.75% |
| Annual Growth Rate | N/A |
| 5-Year Change | -102.77% |
| 10-Year Change | -105.17% |
| Growth Volatility | 179.76 |
Uniqure NV - Net Assets Trend (2010–2024)
This chart illustrates how Uniqure NV's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Uniqure NV (2010–2024)
The table below shows the annual net assets of Uniqure NV from 2010 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-6.75 Million | -103.25% |
| 2023-12-31 | $207.67 Million | -56.37% |
| 2022-12-31 | $476.01 Million | -20.10% |
| 2021-12-31 | $595.78 Million | +144.27% |
| 2020-12-31 | $243.91 Million | -24.50% |
| 2019-12-31 | $323.06 Million | +79.87% |
| 2018-12-31 | $179.61 Million | +99.68% |
| 2017-12-31 | $89.94 Million | +41.35% |
| 2016-12-31 | $63.63 Million | -51.29% |
| 2015-12-31 | $130.63 Million | +149.34% |
| 2014-12-31 | $52.39 Million | +581.89% |
| 2013-12-31 | $7.68 Million | +1396.78% |
| 2012-12-31 | $-592.48K | +82.37% |
| 2011-12-31 | $-3.36 Million | -118.50% |
| 2010-12-31 | $18.17 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Uniqure NV's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 101265551736.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.94 Million | % |
| Other Comprehensive Income | $-52.80 Million | % |
| Other Components | $1.17 Billion | % |
| Total Equity | $-6.75 Million | 100.00% |
Uniqure NV Competitors by Market Cap
The table below lists competitors of Uniqure NV ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
UroGen Pharma Ltd
NASDAQ:URGN
|
$718.63 Million |
|
Gujarat Gas Limited
NSE:GUJGASLTD
|
$718.69 Million |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
$718.91 Million |
|
Legend Holdings Corporation
PINK:LGNRF
|
$719.23 Million |
|
Esquire Financial Holdings Inc
NASDAQ:ESQ
|
$718.22 Million |
|
CytomX Therapeutics Inc
NASDAQ:CTMX
|
$718.16 Million |
|
Astria Therapeutics Inc
NASDAQ:ATXS
|
$718.13 Million |
|
Shenzhen Feima International Supply Chain Co Ltd
SHE:002210
|
$718.01 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Uniqure NV's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 207,670,000 to -6,752,000, a change of -214,422,000 (-103.3%).
- Net loss of 239,556,000 reduced equity.
- New share issuances of 2,123,000 increased equity.
- Other comprehensive income increased equity by 753,000.
- Other factors increased equity by 22,258,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-239.56 Million | -3547.93% |
| Share Issuances | $2.12 Million | +31.44% |
| Other Comprehensive Income | $753.00K | +11.15% |
| Other Changes | $22.26 Million | +329.65% |
| Total Change | $- | -103.25% |
Book Value vs Market Value Analysis
This analysis compares Uniqure NV's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $-0.19 | $15.62 | x |
| 2012-12-31 | $-0.03 | $15.62 | x |
| 2013-12-31 | $0.44 | $15.62 | x |
| 2014-12-31 | $3.06 | $15.62 | x |
| 2015-12-31 | $5.92 | $15.62 | x |
| 2016-12-31 | $2.54 | $15.62 | x |
| 2017-12-31 | $3.33 | $15.62 | x |
| 2018-12-31 | $5.04 | $15.62 | x |
| 2019-12-31 | $8.08 | $15.62 | x |
| 2020-12-31 | $5.49 | $15.62 | x |
| 2021-12-31 | $12.72 | $15.62 | x |
| 2022-12-31 | $10.19 | $15.62 | x |
| 2023-12-31 | $4.36 | $15.62 | x |
| 2024-12-31 | $-0.14 | $15.62 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Uniqure NV utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -883.35%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-77.75%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-22.09 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-19.40 Million |
| 2013 | -482.03% | -911.32% | 0.08x | 7.00x | $-37.80 Million |
| 2014 | -85.97% | -790.61% | 0.05x | 2.22x | $-50.28 Million |
| 2015 | -59.82% | -758.41% | 0.04x | 2.03x | $-91.21 Million |
| 2016 | -115.31% | -292.35% | 0.13x | 2.99x | $-79.74 Million |
| 2017 | -89.38% | -613.33% | 0.06x | 2.32x | $-89.38 Million |
| 2018 | -46.38% | -738.25% | 0.04x | 1.53x | $-101.26 Million |
| 2019 | -38.45% | -1705.82% | 0.02x | 1.39x | $-156.51 Million |
| 2020 | -51.26% | -333.27% | 0.11x | 1.40x | $-149.41 Million |
| 2021 | 55.32% | 62.90% | 0.65x | 1.36x | $270.01 Million |
| 2022 | -26.64% | -119.07% | 0.15x | 1.48x | $-174.39 Million |
| 2023 | -148.54% | -1947.09% | 0.02x | 4.00x | $-329.25 Million |
| 2024 | 0.00% | -883.35% | 0.05x | 0.00x | $-238.88 Million |
Industry Comparison
This section compares Uniqure NV's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Uniqure NV (QURE) | $228.75 Million | 0.00% | 2.88x | $718.41 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |